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Abstract 
Background: Onchocerca lupi and Cercopithifilaria spp. are vector‑borne filarioids of dogs, which harbour skin 
microfilariae (mfs), the former being of zoonotic concern. Proper treatment studies using compounds with microfila‑
ricidal activity have not been performed. Therefore, this study aimed to assess the efficacy of a commercially available 
spot‑on formulation containing moxidectin 2.5%/imidacloprid 10% for the treatment of O. lupi or Cercopithifilaria spp. 
skin‑dwelling mfs in naturally infected dogs.
Methods: Privately owned dogs (n = 393) from southern Portugal were sampled via skin biopsies to identify and 
count mfs in 20 µl of skin sediment. A total of 22 mfs‑positive dogs were allocated to treatment group (n = 11; G1) or 
left untreated as a control (n = 11; G2). As a pilot investigation to test the treatment efficacy, five dogs assigned to G1 
were treated four times at monthly intervals with moxidectin 2.5%/imidacloprid 10% spot‑on formulation on SDs 0, 
28 (± 2), 56 (± 2), and 84 (± 2). Based on the negative results for both O. lupi and/or Cercopithifilaria spp. mfs of dogs in 
the pilot study from SD28 onwards, the remaining six dogs in G1 were treated at SD0 and assessed only at SD28.
Results: Of the 393 animals sampled, 78 (19.8%) scored positive for skin‑dwelling mfs. At the pilot investigation, a 
mean number of 19.6 mfs for O. lupi was recorded among five infected dogs whereas no mfs were detected at SD28. 
At SD0, the mean number of Cercopithifilaria spp. larvae was 12.6 for G1 and 8.7 for G2. The mean number of mfs for 
G2 was 20.09.
Conclusions: Results herein obtained suggest that a single treatment with moxidectin 2.5%/imidacloprid 10% spot‑
on formulation is efficacious against skin‑dwelling mfs in dogs. The microfilaricidal effect of moxidectin could also be 
useful in reducing the risk of O. lupi infection for humans.
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Background
Vector-borne filarioids are transmitted by a wide range 
of arthropods (e.g., mosquitoes, fleas, blackflies, biting 
midges and ticks). About 12 species belonging to the 
genera Acanthocheilonema, Brugia, Cercopithifilaria, 
Dipetalonema, Dirofilaria, and Onchocerca infect dogs 
[1–4]. Among these, the species Dirofilaria repens and 
Dirofilaria immitis are the best-known filarioids in vet-
erinary parasitology for their worldwide distribution 
and their zoonotic potential [5–7]. The genus Oncho-
cerca includes 30 species primarily infecting ungulates 
[8] and, to a lesser extent, carnivores and humans. In 
the last decade, the increased number of zoonotic 
cases of O. lupi has stimulated the interest of the sci-
entific community in this little-known parasite [9–11]. 
Since the first molecularly confirmed case of infection 
by O. lupi in humans [9], to date, 22 patients have been 
diagnosed with this onchocercid species in Germany, 
Tunisia, Hungary, Greece, Turkey, Iran, and the USA 
[12–15]. Consequently, much more attention is cur-
rently given to the distribution and clinical significance 
of O. lupi in dogs. In the initial stage, canine onchocer-
cosis is associated with nonspecific ocular discomfort 
(i.e. excessive lacrimation, photophobia, conjunctivi-
tis, exophthalmos, and periorbital swelling), while in 
the chronic phase the typical nodules are detected on 
the external parts of the ocular apparatus (i.e. eyelids, 
nictitating membrane, conjunctiva, and sclera) [16]. 
However, dogs do not always display overt clinical signs 
when O. lupi adults localize in the retrobulbar space of 
the eye [17]. Moreover, adult nematodes may localise in 
other anatomical districts other than the ocular appa-
ratus, given that microfilariae (mfs) were diagnosed in 
dogs with absence of nodules together with the lack of 
ocular lesions at ultrasound examination [18].
The arthropod species involved in the life cycle of O. 
lupi have not been identified so far. Blackflies of the spe-
cies Simulium velutinum, Simulium reptans, and Simu-
lium pseudequinum, which fed on an O. lupi-infected dog 
from Greece, did not demonstrate progression of nema-
tode larval development [19]. However, O. lupi DNA has 
been found in Simulium tribulatum blackflies from the 
USA [20].
Dogs may also be infected by at least three species of 
Cercopithifilaria, namely Cercopithifilaria grassii, Cerco-
pithifilaria sp. II sensu Otranto et al. 2013 (a formal tax-
onomic description of adults for this species is lacking), 
and C. bainae [21]. In particular, C. bainae is prevalent 
in canine and tick populations from Southern and East-
ern Europe (i.e. Spain, Italy, Greece, Portugal, and Roma-
nia) [22–24]. In addition, the parasite has been reported 
in Australia, Brazil, Malaysia, South Africa, and the USA 
[25, 26]. Generally, the parasite distribution overlaps 
that of its vector, the brown dog tick Rhipicephalus san-
guineus sensu lato  [27–29]. However, C. bainae is con-
sidered of minor importance in veterinary medicine with 
few reports of erythematous, papular, and pruritic der-
matitis [21, 26] and chronic polyarthritis [30] associated 
with the infection in dogs.
The diagnosis of canine onchocercosis and cercopithi-
filarioses is achieved by the microscopic detection and 
identification of mfs in skin biopsies [9, 31, 32] or PCR-
based techniques [9, 33, 34]. Preliminary investigations 
to develop tools able to detect anti-O. lupi antibodies 
have also been carried out [35–37]. Treatment of clini-
cal cases of canine onchocercosis has been attempted 
using combinations of melarsomine, ivermectin, topical 
and systemic antibiotics, and prednisone [15, 16, 38]. A 
single dog presenting erythematous lesions and affected 
by C. bainae was successfully treated with a spot-on for-
mulation containing imidacloprid 10% and moxidectin 
2.5% [26]. In addition, the administration of oxfenda-
zole (50 mg/kg/PO for 5 or 10 consecutive days) in dogs 
was ineffective in reducing skin-dwelling O. lupi mfs and 
showed a not statistically significant reduction of 50% 
of ocular lesions in a 6-month follow-up period [39]. 
However, proper studies on the long-term outcomes of 
macro- and microfilaricidal therapies for treating both 
parasites have not yet been performed, and no indica-
tions for the best treatment protocol to use are available. 
We assessed the efficacy of a commercially available spot-
on formulation containing moxidectin and imidacloprid 
for the treatment of O. lupi or Cercopithifilaria spp. skin-
dwelling mfs in naturally infected dogs.
Materials and methods
Ethics statement
The trial was a negative control, and clinical efficacy 
study partially blinded using a randomized block design, 
conducted according to the standards of Good Scien-
tific Practice (GSP) and the national animal welfare 
requirements. Privately owned dogs, which lived in an 
area endemic for O. lupi and Cercopithifilaria spp. of 
the Algarve region (southern Portugal), were enrolled 
[39, 40]. At the end of the study all dogs were treated 
with Advocate® spot-on (Bayer Animal Health) and all 
screened dogs were dewormed with Drontal® Plus (Bayer 
Animal Health).
Sampling procedure, enrolment and follow‑up
From May to December 2018, 393 privately owned dogs 
(i.e. 242 males and 151 females) were sampled via skin 
biopsies for diagnosing O. lupi and Cercopithifilaria 
spp. infection. All animals came from the municipali-
ties of southern Portugal, i.e. Benafim (latitude: 37°13′N; 
longitude: 8°07′W), Boliqueime (latitude: 37°08′N; 
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longitude: 8°09′W), Guia  (latitude: 37°07′N; longitude: 
8°17′W), Lagos (latitude: 37°09′N; longitude: 8°44′W), 
Marmelete  (latitude: 37°18′N; longitude: 8°40′W), Mata 
Lobos (latitude: 37°08′N; longitude: 8°01′W),  Monte 
Seco (latitude: 37°10′N; longitude: 8°05′W),  Parragil 
(latitude: 37°9′N; longitude: 8°05′W),  Patacão  (latitude: 
37°3′N; longitude: 7°57′W),  Picota (latitude: 37°09′N; 
longitude: 8°06′W),  Salir (latitude: 37°14′N; longi-
tude: 8°03′W),  Tavira (latitudine: 37°07′N; longitudine: 
7°38′W), and Tunes (latitude: 37°10′N; longitude: 8°15′W) 
(Fig. 1). Inclusion criteria were living outdoors or having 
regular outdoor activities and being at least 8  weeks of 
age and weighing > 1 kg. Dogs were excluded when they 
were treated with macrocyclic lactones 6  weeks before 
study start or when they were pregnant and/or lactating. 
All skin samples were collected using a 4-mm-diameter 
skin punch. Before the biopsy, the skin was disinfected 
with 70% alcohol and a 4% chlorhexidine solution fol-
lowed by local anaesthesia with 2% lidocaine hydrochlo-
ride. Biopsies were taken from the interscapular regions 
of the dogs and soaked in 2  ml saline solution (NaCl 
0.9%) for at least 12 h. After the procedure, the wounds 
on the dogs’ skin were closed with Histoacryl® (Braun) or 
a Sterile Disposable Skin Stapler as per the owners’ pref-
erences. Dogs were enrolled when O. lupi or Cercopithi-
filaria spp. mfs were detected in 20 µl of skin sediment 
and their number was recorded in individual forms.
On study day (SD) 0, dogs were weighed and their 
body weight recorded with the purpose of dosing the 
pharmaceutical product used. Twenty-two dogs meet-
ing the inclusion criteria were included in the study 
and allocated to treatment group (n = 11; G1) or left 
untreated as control (n = 11; G2) following a random 
treatment allocation plan on the basis of an inclusion 
sequence. As a pilot investigation to test the treat-
ment efficacy, five dogs assigned to G1 were treated 
four times at monthly intervals with Advocate® spot-
on (Bayer Animal Health), on SDs 0, 28 (± 2), 56 (± 2), 
and 84 (± 2), at the minimum recommended dose rate 
of 2.5 mg moxidectin/kg body weight (BW) and 10 mg 
imidacloprid/kg BW corresponding to ≥ 0.1  ml spot-
on formulation per kg BW. Dogs were treated with 
the appropriate pipette size according to their weight. 
Based on the negative results for both O. lupi or Cer-
copithifilaria spp. mfs obtained in animals treated in 
the pilot study, from SD28 onwards, the remaining six 
dogs in G1 were treated and assessed only once, at SD0 
and SD28, respectively. The 11 animals in the control 
group (G2) were left untreated, but samples for diagno-
sis were taken at the same time point of the six animals 
left in G1.
Molecular identification
Microfilariae were isolated and genomic DNA 
extracted using a commercial kit (DNeasy Blood & 
Tissue Kit, Qiagen, Germany) in accordance with the 
manufacturer’s instructions. Samples were molecularly 
processed for specific amplification and sequencing of 
the partial cytochrome oxidase subunit 1 (cox1) gene 
(~ 689  bp), following procedures described elsewhere 
using generic primers for filarioids [21]. Amplicons 
obtained from the skin sediments were purified using 
Ultrafree-DA columns (Amicon, Millipore, USA) and 
sequenced directly with the Taq DyeDeoxyTerminator 
Cycle Sequencing Kit (v.2, Applied Biosystems, USA) 
in an automated sequencer (ABI-PRISM 377, Applied 
Biosystems).
Sequences were aligned using the Geneious R9 soft-
ware package (http:// www. genei ous. com) and com-
pared (BLASTn) with those available in the GeneBank 
database (http:/ blast.ncbi.nlm.nih.gov/Blast.cgi).
Calculation of the efficacy and statistical analyses
The percentage (%) of reduction [t] of mfs was calculated 
as follows: [t] = [(Ct0–Ct)/Ct0] × 100, where Ct0 is the 
baseline count before treatment and Ct was the count 
at any time point (t). Moreover, efficacy (%) = [(Ct–T)/
Ct] × 100, where Ct is the mean count of mfs of the con-
trol group at X time and T is the mean count of mfs of 
the treated animal groups at X time, was calculated 
and demonstrated by Fisher’s exact test on contingency 
tables. Fisher’s exact test was also performed to compare 
and assess the risk of mf infection according to the age 
and sex of the animals. Statistical analysis was planned 
and conducted in compliance with current guidelines 
[41]. Statistical calculations and randomization were per-
formed with SPSS® statistical package for Windows, ver-
sion 13.0, and nQuery + nTerim 3.0 (StatSols), Statistical 
Solutions® Ltd. 2014, Microsoft.
Results
Of the 393 animals sampled, 78 (19.8%; CI 16.1‒24.2) 
scored positive for skin-dwelling mfs. Specifically, 72 
only for Cercopithifilaria spp. mfs (18.3%; CI 14.7‒22.5), 
2 only for O. lupi (0.5%; CI 0.1‒1.9) mfs, and 4 (1.0%; CI 
0.4‒2.6) for both, with an overall prevalence of 19.3% 
(CI 15.6‒23.5) for Cercopithifilaria spp. and of 1.5% 
(CI 0.7‒3.3) for O. lupi (Fig.  2). Risk estimates for the 
infection demonstrated that males are more prone to 
be infected by Cercopithifilaria spp. mfs than females 
(p = 0.01; odds ratio: 2.1; 95% CI 1.2‒3.8). In contrast, the 
age of the animals evaluated was not statistically signifi-
cant for mfs infection (p > 0.05).
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At the cross-sectional study, of the 76 animals infected 
by Cercopithifilaria spp. (Fig. 2), C. bainae was the most 
prevalent species (n = 72; 18.3%; 95% CI 14.7‒22.5), fol-
lowed by Cercopithifilaria sp. II (n = 9; 2.3%; 95% CI 
1.2‒4.3) and C. grassii (n = 5; 1.3%; 95% CI 0.5‒3.0), with 
9 animals being infected by one or more species of Cer-
copithifilaria. The mean number of O. lupi mfs (23; SD 
34.76) was higher than that of C. bainae (mean 5.3; SD 
8.4), C. grassii (mean 3.6; SD 3.4), and Cercopithifilaria 
sp. II (mean 3.7; SD 3.5).
At SD0, the mean number of Cercopithifilaria spp. mfs 
was 12.6 (SD: 13.9; 95% CI 3.3‒22.0) for G1 and 8.7 (SD: 
6.6; 95% CI 4.3‒13.2) for G2, with no statistically signifi-
cant difference among both groups (p > 0.05). A mean 
number of 19.6 (SD: 20.2; 95% CI: 5.5‒44.7) for O. lupi 
was recorded among five infected dogs in G1. At SD28 
no mfs were detected in G1, therefore indicating 100% 
efficacy for the employed treatment after the first appli-
cation. The count number of O. lupi and Cerchopithifi-
laria spp. microfilarie for G1 and G2 at SD0 and SD28 
is reported in Table  1. Dogs did not present clinical 
signs suggestive for infection by O. lupi and/or Cerco-
pithifilaria spp. The morphological identification of mfs 
was molecularly confirmed, and nucleotide sequences 
obtained from microfilarial DNA displayed 100% iden-
tity with those of O. lupi from Portugal (GenBank; acces-
sion number: EF521410), C. bainae (GenBank; accession 
number: JF461457), Cercopithifilaria sp. II (GenBank; 
accession number: JQ837809), and C. grassii (GenBank; 
accession number: JQ837810).
Discussion
A single administration of moxidectin/imidacloprid 
spot-on formulation (Advocate® spot-on) was shown to 
be efficacious for the treatment of skin-dwelling mfs in 
naturally infected dogs. This has been assessed through 
counting mfs in the sediment of skin biopsy punches 
obtained pre- and post-treatment by comparison with 
untreated control animals positive for Cercopithifilaria 
spp. mfs. Based on the preliminary results in 5 animals, 
the remaining 17 animals were checked for mfs only on 
SD28, also considering the reluctancy of animal owners 
Fig. 1 Map of the three areas in Algarve, Portugal, where the study was conducted (insert up left part) with a detail of the localities from where 
dogs were sampled (red dots)
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to authorize collection of multiple skin biopsies, which is 
a rather invasive procedure.
The efficacy of a single administration of a moxidectin/
imidacloprid spot-on formulation is expected because 
the product is currently licensed in Europe for the hemo-
prophylaxis of D. immitis and D. repens. Furthermore, the 
product is labelled for microfilaria treatment based on 
the microfilaricidal efficacy of moxidectin against blood-
circulating mfs. This has been demonstrated herein also 
against skin-dwelling mfs of Cercopithifilaria spp. and 
it is suggestive also for O.  lupi. Nonetheless, since rein-
fection may be an issue, in endemic areas, the treatment 
should be kept monthly to avoid new infection.
Overall, to our knowledge this is the first evidence-
based protocol for cleaning O. lupi mfs infections since 
efficacy of  drugs has been mainly assessed  for curing 
nodules [42].
Indeed, avermectins have been used for treating O. lupi 
nodules in dogs in different formulations and timing. For 
example, other treatment protocols previously adopted 
included moxidectin (i.e. 0.22  mg/kg subcutaneous 
injection administered, followed by two additional injec-
tions at monthly intervals), doxycycline (5  mg/kg orally 
twice daily for 3 months), and following monthly recheck 
examinations and a final moxidectin injection, and pro-
phylactic oral heartworm therapy (400 µg/kg orally every 
day for 30  days) [16]. Also, ivermectin administered at 
150 μg/kg/dose every 3 months was successfully used for 
curing nodules [43]. While previous studies conducted 
in Greece demonstrated that ivermectin cured and pre-
vented infection in 23 dogs with subconjunctival oncho-
cerciasis [44], 16 ivermectin-treated dogs in the USA 
showed a 67% infection recurrence [38]. This could be 
due to the strain of O. lupi circulating in the USA or to 
specific epidemiological conditions that are yet unknown 
[45].
Similarly, the moxidectin/imidacloprid spot-on formu-
lation herein tested was shown to be efficacious against 
mfs of Cercopithifilaria spp. This study confirms a previ-
ous report which suggested the efficacy of the imidaclo-
prid/moxidectin spot-on formulation in association with 
prednisone in treating C. bainae-caused dermatitis in the 
USA [26].
Fig. 2 Light microscopy of microfilariae of a Onchocerca lupi, b Cercopithifilaria bainae c Cercopithifilaria sp. II sensu Otranto et al., 2013, and d 
Cercopithifilaria grassii 
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The prevalence of infection by O. lupi at the initial 
screening (i.e. 1.5%) was lower than that recorded in a 
previous study in the same geographical area (i.e. 8% [40]; 
17.1% [39]). However, due to the knowledge gaps in the 
life cycle of this filarioid (e.g. the identity of the vector 
is unknown), the epidemiology of the infection remains 
rather obscure. On the other hand, for Cercopithifilaria 
spp. the overall prevalence herein detected (19.8%) is 
similar to that previously reported in the same area in 
Portugal (i.e. 23.5%; [23]) and in central Spain (i.e. 21.6%; 
[21]). Particularly, C. bainae was the most prevalent spe-
cies, followed by Cercopithifilaria sp. II and C. grassii as 
reported in the same geographical area [23].
Conclusions
Results obtained in this study indicate that mox-
idectin/imidacloprid spot-on formulation seems to 
be efficacious for the treatment of O. lupi and Cerco-
pithifilaria spp. skin-dwelling mfs in infected dogs in 
a single administration. Therefore, this treatment may 
prove useful for the prevention of the infection caused 
by these little-known filarioids. Finally, assessing the 
microfilaricidal efficacy in dogs could also be useful in 
reducing the risk of O. lupi infection for humans.
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Table 1 Sex, age, breed, and microfilariae counting number for dogs of the treatment (G1) and control (G2) groups enrolled in this 
study
Microfilariae counting was performed at SD0 and reassessment at SD28 for all animals in both groups
Ol Onchocerca lupi, Cs Cercopthifilaria spp., Cb Cercopthifilaria bainae, Cg Cercopthifilaria grassi
* Animals included in the pilot study as they received the treatment and were assessed for mfs on SD0, SD28, SD56, and SD84, remaining negative
Study group Serial number of 
dogs
Sex Age (years) Breed SD0 (no. of larvae) SD28 (no. of larvae)
G1 (Treatment) 5* M  > 1 to < 5 Portuguese Warren Hound 52 (Ol) + 29 (Cs) Neg
11* M  ≥ 5 Mongrel 26 (Ol) + 4 (Cs) Neg
13* M  ≥ 5 Portuguese Warren Hound 5 (Ol) + 1 (Cs) Neg
18* M  ≥ 5 Portuguese Warren Hound 12 (Ol) Neg
21* M  ≥ 5 Barrocal Algarvio 3 (Ol) + 12 (Cs) Neg
315 F  ≥ 5 Pitbull 2 (Cb) Neg
346 M  ≥ 5 Portuguese Warren Hound 34 (Cb) Neg
373 F  ≤ 1 Anglo‑French hound 3 (Cb) Neg
414 M  > 1 to < 5 Mongrel 17 (Cb) Neg
442 M  ≥ 5 Grand Bleu de Gascogne 35 (Cb) Neg
450 M  ≤ 1 Barrocal Algarvio 2 (Cb) Neg
G2 (Control) 313 M  ≥ 5 Portuguese Warren Hound 9 (Cg) 10 (Cg)
320 M  > 1 to < 5 Portuguese Warren Hound 14 (Cb) 5 (Cb)
323 M  > 1 to < 5 Dogo Argentino x Pitbull 24 (Cb) 47 (Cb)
327 M  > 1 to < 5 Portuguese Warren Hound 4 (Cb) Neg
333 M  > 1 to < 5 Portuguese Warren Hound 5 (Cb) 3 (Cb)
381 M  > 1 to < 5 Paderne 2 (Cb) 26 (Cb)
382 M  ≤ 1 Dogo Argentino 6 (Cb) 12 (Cb)
385 M  > 1 to < 5 Dogo Argentino 12 (Cb) 20 (Cb)
418 M  > 1 to < 5 Mongrel 5 (Cb) 4 (Cb)
425 M  > 1 to < 5 Mongrel 13 (Cb) 12 (Cb)
451 M  ≤ 1 Paderne × Barrocal Algarvio 2 (Cb) 82 (Cb)
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